ERASCA, INC.
Last · NASDAQ$14.70-0.08 (-0.54%)close · yahoo · 16h ago
Market cap$5.14B349.8M sh
P/E · TTM-15.5fwd -23.6 · eps -0.95 · loss
Beta0.62vs S&P 500
Div yield0.00%annual · TTM
52w range
$2.105$24.28
Volume4.7Msession
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-03-12
- Operating Cf Burn
- Cash Runway Low
- Accumulated Deficit High
Red flags
- Operating Cf Burn — Negative operating cash flow
- Cash Runway Low — Cash runway ~0.8 years
- Accumulated Deficit High — Accumulated deficit / equity 274%
Upcoming earnings
9:00 PM UTC+1
Period
Sep 2026
Est. EPS
−$0.13
Est. revenue
0
Press & signals
- GlobeNewswire
Erasca Reports Second Quarter 2026 Business Updates and Financial Results
- GlobeNewswire
Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- GlobeNewswire
Erasca Strengthens R&D Leadership with Appointment of Internationally Recognized Medical Oncologist Charles S. Fuchs, M.D., M.P.H., as President of R&D
The rest of this company's wire — with summaries and source links — is part of Pro.
See plansDocuments
FormReporting forFiledFlags